Recently added Catalysts

REGN7508

Phase 3

Atrial Fibrillation (AF) | Small molecule | Cardiovascular |Regeneron Pharmaceuticals, Inc.|Last Updated: Jul 23, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLEDDMC

Total Trials3

Total Enrollment19,192

FDA Designations

No designations recorded

Clinical trial landscape

REGN7508 · 11 trials · 7 indications

Phase 3 8Phase 2 2Phase 1 1

Indication

NCT07697599Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)Venous Thromboembolism (VTE)

NOT YET_RECRUITING1,908 Analytics

NCT07626411Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationAtrial Fibrillation (AF)

NOT YET_RECRUITING15,364 Analytics

NCT07318610Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery DiseasePeripheral Artery Disease (PAD)

RECRUITING7,050 Analytics

NCT07493304Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersVenous Thromboembolism (VTE)

RECRUITING1,600 Analytics

NCT07430956Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is UnsuitableAtrial Fibrillation (AF)

RECRUITING2,628 Analytics

NCT07410117REGN7508 in Adult Participants for Prevention of Cancer-Associated ThrombosisCancer-Associated Thrombosis (CAT)

RECRUITING1,120 Analytics

NCT07213778REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsSymptomatic Venous Thromboembolism (VTE)

RECRUITING2,000 Analytics

NCT07015905REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsVenous Thromboembolism (VTE)

RECRUITING2,000 Analytics

PHASE3NOT YET_RECRUITING

Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)

Venous Thromboembolism (VTE)

NCT076975991,908

Unlock trial analytics

PHASE3NOT YET_RECRUITING

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

Atrial Fibrillation (AF)

NCT0762641115,364

Unlock trial analytics

PHASE3RECRUITING

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

Peripheral Artery Disease (PAD)

NCT073186107,050

Unlock trial analytics

PHASE3RECRUITING

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Venous Thromboembolism (VTE)

NCT074933041,600

Unlock trial analytics

PHASE3RECRUITING

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

Atrial Fibrillation (AF)

NCT074309562,628

Unlock trial analytics

PHASE3RECRUITING

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Cancer-Associated Thrombosis (CAT)

NCT074101171,120

Unlock trial analytics

PHASE3RECRUITING

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

Symptomatic Venous Thromboembolism (VTE)

NCT072137782,000

Unlock trial analytics

PHASE3RECRUITING

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Venous Thromboembolism (VTE)

NCT070159052,000

Unlock trial analytics

Study Endpoints

Primary Endpoints

Time-to-first event of centrally adjudicated VTE [symptomatic VTE or incidental VTE or asymptomatic VTE]

Approximately 6 months

Time-to-first event of centrally adjudicated International Society on Thrombosis and Haemostasis (ISTH)-defined major bleeding or Clinically Relevant Non-Major (CRNM) bleeding

Approximately 6 months

Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism

Approximately 36 months

Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding

Approximately 36 months

Time-to-first occurrence of a major thrombotic vascular event, consisting of Acute Limb Ischemia (ALI), major amputation (above the ankle) of vascular etiology, Myocardial Infarction (MI), ischemic stroke, or Cardiovascular (CV) death

Approximately up to 42 months

Cohort 1

Time-to-first occurrence of International Society of Thrombosis and Hemostasis (ISTH) major or Clinically Relevant Non-major (CRNM) bleeding

Approximately up to 42 months

Cohort 1 and 2

Occurrence of Treatment-Emergent Adverse Events (TEAEs)

Approximately 6 months

Part 1

Severity of TEAEs

Approximately 6 months

Part 1

Time-to-first event of centrally adjudicated recurrent VTE [DVT (symptomatic or asymptomatic [proximal] or Non-fatal PE (symptomatic or asymptomatic [in a segmental or larger pulmonary artery] )or VTE-related death)]

Up to approximately 3.5 years

Part 2

Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH)-defined major bleeding or Clinically Relevant Non-Major (CRNM) bleeding

Up to approximately 3.5 years

Part 2

Time to first occurrence of ischemic stroke or systemic embolism

Up to 36 months

Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding

Up to 36 months

Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death

Through 6 months

Time-to-first event of centrally adjudicated International Society of Thrombosis and Hemostasis (ISTH) major bleeding or Clinically Relevant Non-Major (CRNM) bleeding

Through 6 months

Incidence of the composite endpoint of symptomatic VTE and all-cause death

Through day 30 visit

Incidence of the composite endpoint of asymptomatic or symptomatic Venous Thromboembolism (VTE) [including VTE-related death]

Through day 12 visit, approximately 14 days

Incidence of any bleeding

12 weeks

Defined as the composite of International Society on Thrombosis and Haemostasis (ISTH) major bleeding, ISTH Clinically Relevant Non-Major (CRNM) bleeding, or minor bleeding

Percentage of Participants With Confirmed, Adjudicated Venous Thromboembolism (VTE)

Through day 12

Composite endpoint that includes asymptomatic deep DVT (deep venous thrombosis) detected by unilateral venography of the operated leg; confirmed symptomatic DVT of either leg; confirmed fatal or nonfatal pulmonary embolism (PE) including unexplained death for which PE cannot be ruled out.

Incidences of treatment-emergent adverse events (TEAE)

Up to 36 days

Treatment-emergent adverse events are defined as those that are not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period.

Severity of TEAE

Up to 36 days

Treatment-emergent adverse events are defined as those that are not present at baseline or represent the exacerbation of a pre-existing condition during the on-treatment period.

Secondary Endpoints

Time-to-first event of centrally adjudicated symptomatic VTE [symptomatic Deep Vein Thrombosis (DVT) or symptomatic non-fatal Pulmonary Embolism (PE) or VTE-related death]

Approximately 6 months

Time-to-first event of symptomatic DVT

Approximately 6 months

Time-to-first event of symptomatic non-fatal PE

Approximately 6 months

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED

MaskingQUADRUPLE

ModelPARALLEL

PurposeTREATMENT

Treatment Arms

Arm	Type	Description
REGN7508	EXPERIMENTAL	-
REGN9933	EXPERIMENTAL	-
Placebo	PLACEBO_COMPARATOR	-
REGN7508 + Placebo	EXPERIMENTAL	-
Apixaban + Placebo	ACTIVE_COMPARATOR	-
Cohort 1	EXPERIMENTAL	-
Cohort 2	EXPERIMENTAL	-
Apixaban	ACTIVE_COMPARATOR	-
REGN7508 and Placebo	EXPERIMENTAL	-
Placebo and ASA	ACTIVE_COMPARATOR	-
IV REGN7508	EXPERIMENTAL	-
IV Placebo, SC REGN7508	EXPERIMENTAL	-
IV Placebo, apixaban	ACTIVE_COMPARATOR	-
IV Placebo, enoxaparin	ACTIVE_COMPARATOR	-
Enoxaparin	ACTIVE_COMPARATOR	-
Cohort 1 Lowest IV Dose	EXPERIMENTAL	Randomized 3:1
Cohort 2 Low IV Dose	EXPERIMENTAL	Randomized 3:1
Cohort 3 Mid IV Dose	EXPERIMENTAL	Randomized 3:1
Cohort 4 High IV Dose	EXPERIMENTAL	Randomized 3:1
Cohort 5 Higher IV Dose	EXPERIMENTAL	Randomized 3:1
Cohort 6 High SC Dose	EXPERIMENTAL	Randomized 3:1
Cohort 7 Higher SC Dose	EXPERIMENTAL	Randomized 3:1
Optional: Cohort 8 Highest IV or SC Dose	EXPERIMENTAL	Randomized 3:1
Cohort 9 High SC Dose	EXPERIMENTAL	Randomized 3:1
Optional: Cohort 10 Highest SC Dose	EXPERIMENTAL	Randomized 3:1

Interventions

Name	Type	Description
REGN7508	DRUG	Administered per the protocol
REGN9933	DRUG	Administered per the protocol
Placebo	DRUG	Administered per the protocol
Apixaban	DRUG	Administered per the protocol
Rivaroxaban	DRUG	Administered per the protocol
Acetylsalicylic Acid (ASA)	DRUG	Administered per the protocol
Enoxaparin	DRUG	Administered per the protocol
REGN7508 (IV)	DRUG	Administered sequential, ascending single intravenous (IV) dose
REGN7508 (SC)	DRUG	Administered sequential, ascending single subcutaneous (SC) dose
Matching Placebo (IV)	DRUG	Administered sequential, ascending single intravenous (IV) dose
Matching Placebo (SC)	DRUG	Administered sequential, ascending single subcutaneous (SC) dose

Unlock Study Design Details

Eligibility Criteria

Age Range15 Years to N/A

SexALL

Healthy VolunteersNo

Key Inclusion Criteria: 1. Is undergoing PICC placement for Intravenous (IV) administration of clinically indicated medications, including chemotherapy, antibiotics, TPN, and/or other indications as described in the protocol 2. Has Eastern Cooperative Oncology Group Performance (ECOG) Status ≤3 or ...

Countries:United StatesGeorgiaJapanGreeceMalaysiaMoldovaBulgariaHungaryLatviaLithuaniaPolandRomaniaArgentinaBrazilCanadaUnited Kingdom

Unlock Eligibility Criteria

Competitive Landscape -Atrial Fibrillation 102 trials (matched to "Atrial Fibrillation (AF)")

Company	Ticker	Trials	Lead Phase	Drugs
Regeneron Pharmaceuticals, Inc.	REGN	2	PHASE3	REGN7508, REGN9933
Johnson & Johnson	JNJ	2	PHASE3	Milvexian, Apixaban
Novartis AG Sponsored ADR	NVS	1	PHASE2	PKN605
Milestone Pharmaceuticals, Inc.	MIST	1	PHASE3	Etripamil
Boston Scientific Corporation	BSX	22	N/A	Undisclosed
Abbott Laboratories	ABT	9	-	Undisclosed
HeartSciences Inc.	HSCS	1	PHASE3	Undisclosed
AtriCure, Inc.	ATRC	5	N/A	Undisclosed
Rhythm Pharmaceuticals, Inc.	RYTM	9	-	Undisclosed
Pulse Biosciences, Inc.	PLSE	4	N/A	Undisclosed
Haemonetics Corporation	HAE	1	N/A	Undisclosed
Medtronic Plc	MDT	7	-	Undisclosed
Cardio Diagnostics Holdings Inc.	CDIO	1	PHASE1	The intervention includes Amiodarone-Infused CardiaMend patches
AstraZeneca PLC	AZN	1	N/A	Undisclosed
Healthcare Services Group, Inc.	HCSG	1	-	Undisclosed
HeartBeam, Inc.	BEAT	1	-	Undisclosed

Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWJul 24, 2026NCT07175428lastUpdatePostDate: changed

LOWJul 22, 2026NCT07410117lastUpdatePostDate: changed

LOWJul 22, 2026NCT07213778lastUpdatePostDate: changed

LOWJul 22, 2026NCT07410117lastUpdatePostDate: changed

LOWJul 22, 2026NCT07213778lastUpdatePostDate: changed

LOWJul 13, 2026NCT07697599NEW_TRIAL: changed

LOWJul 13, 2026NCT07015905lastUpdatePostDate: changed

LOWJul 13, 2026NCT07697599NEW_TRIAL: changed

LOWJul 13, 2026NCT07015905lastUpdatePostDate: changed

LOWJul 10, 2026NCT07318610startDate: changed

LOWJul 9, 2026NCT07213778lastUpdatePostDate: changed

LOWJul 8, 2026NCT07175428lastUpdatePostDate: changed

MEDIUMJun 27, 2026NCT06454630TRIAL_REMOVED: changed

LOWJun 23, 2026NCT07430956lastUpdatePostDate: changed

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

M&A Tracker

News

Blogs

Modality Leaderboard

API

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

REGN7508

Success Probability

Market & Valuation

Trial Design

FDA Designations

Clinical trial landscape

Study Endpoints

Primary Endpoints

Secondary Endpoints

Study Design & Arms

Treatment Arms

Interventions

Eligibility Criteria

Competitive Landscape -Atrial Fibrillation 102 trials (matched to "Atrial Fibrillation (AF)")

Recent Changes (Last 90 Days)